CoLucid Pharmaceuticals
Durham
About CoLucid Pharmaceuticals
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 1 – 10
- Total funding: $97.3M
- Funding stage: M&A
- Last round: Series C (Jan 2015)
- Ticker: nasdaq:CLCD
- Website: colucid.com
- Phone: (919) 649-6184
Industries & Categories
Biotechnology, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/colucid-pharmaceuticals-2031642 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.